Risk Factors Update Summary
- Collaboration partner added to the risk factors, potentially impacting control over product development.
- Development of FHD-286, a selective ATPase inhibitor, progressing with clinical studies in various indications.
- Pipeline reduced from more than 15 to 10 programs, with one clinical-stage drug candidate.
- Strategic collaboration with Lilly confirmed, highlighting the importance of the company's targets.
- Exploration of FHD-286 in various indications, including uveal melanoma and AML, showing promising preclinical and clinical data.
- Increased patent applications from 14 to more than 25, including pending ex-U.S. applications.
- Anticipated filing of at least six INDs over the next four years, validating potential growth.
- Potential filing of IND by Lilly in the second quarter of 2024 for FHD-909, a BRG1 inhibitor.
- Addition of new competitors like Prelude Therapeutics Incorporated and Plexium, Inc.
- Reduction in full-time employees from 161 to 116, impacting research and development capabilities.
- Accumulated deficit increased from $373 million to $471 million.
- Change in stock ownership percentage from 37% to 39% by affiliates, affecting control.
Full Text Changes in Most Recent 10-K
Intended use: review the highlighted statements. These are additions to the risk factors disclosure in the most recent 10-K filing compared to the previous 10-K filing. Deleted and moved text is less important and is shown for context.
To view the full company filings, click on the following link to be taken to the SEC EDGAR database landing page for the company: https://www.sec.gov/edgar/browse/?CIK=1822462&owner=exclude
This content requires a 'Free' membership to view. Please create one here.
This content requires a 'Free' membership to view. Please create one here.